Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Adolescent (13 to 18 years)","concept":{"vocab":"MeSH","vocabURI":"D000293"}},{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Patients aged over 18 years Hospitalised for less than 3 days for any reason whatsoever, but screened for Covid-19. SARS-CoV-2 infection should be \"probable\" or \"confirmed\" according to the definition published on 3 April by Santé Publique France (French Public Health Agency): laboratory confirmation (by positive RT-PCR further to nasopharyngeal sample or any other sample and/or positive serology indicating infection) or by a composite endpoint combining characteristic pulmonary impairment upon imaging and clinical/laboratory effects suggesting viral infection (including: fever, cough, chest pain, and biological inflammatory syndrome, lymphopenia, elevated liver enzymes). Registered with a social security scheme or a beneficiary of such a scheme The patient or their representative will have received information on the study and signed the emergency informed consent/inclusion form in compliance with Article L.1122-1-3 of the French Public Health Code (CSP)","clusion_E":""}